RenovaCare, Inc. (OTCMKTS:RCAR) Files An 8-K Entry into a Material Definitive Agreement

RenovaCare, Inc. (OTCMKTS:RCAR) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement

On June 4, 2019 RenovaCare, Inc. (the “Company”) and Roger Esteban-Vives (“REV”), executed an executive services consulting agreement, effective June 1, 2019, a form of which is attached as Exhibit 10.1 hereto, in which REV, will serve as the Company’s Vice President of Research & Product Development. to an Executive Services Consulting Agreement, Dr. Esteban-Vives will be compensated $10,000 per month and, at the discretion of the Board, he shall be eligible for equity stock options or equity awards to the Company\’s equity incentive compensation plans in effect from time to time.

Between November 2016 and June 2019, Dr. Esteban-Vives served as a Director of Cell Sciences for the Company, during which time he interacted with regulatory agencies and provided support for the investigation, evaluation, and development of new clinical indications and protocols. Between October

2010 and August 2016, Dr. Esteban-Vives was a Research Associate at the McGowan Institute of Regenerative Medicine, University of Pittsburgh (Pittsburgh, USA). During this time he was involved in the research, investigation, experimentation, and implementation of clinical protocols to treat burn patients using a combination of autologous epidermal-dermal skin cell isolation, and cell-spray technology.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

The following exhibit is filed herewith:

10.1 Executive Services Consulting Agreement, dated June 4, 2019, and effective June 1, 2019, by and between RenovaCare, Inc. and Roger Esteban-Vives.

  


RenovaCare, Inc. Exhibit
EX-10.1 2 exh_101.htm EXHIBIT 10.1 Exhibit 10.1     Renovacare,…
To view the full exhibit click here

Story continues below

About RenovaCare, Inc. (OTCMKTS:RCAR)

RenovaCare, Inc., formerly Janus Resources, Inc., is a biotechnology company. The Company is focused on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The Company’s initial products under development target skin. The Company, through RenovaCare Sciences Corp., offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). It is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Its technology, the CellMist System, uses SkinGun to spray a liquid suspension of a patient’s stem cells, the CellMist Solution, onto wounds. The CellMist System harvests a patient’s stem cells from a small area of skin and suspends them in the water-based CellMist Solution.

An ad to help with our costs